Debdeep Samaddar

Consultant Medical and Heamto-oncologist, Manipal Hospital EM Bypass and Broadway, Kolkata

[Debdeep Samaddar @DebdeepSamaddar]

Our Indian real-world study of adjuvant CDK4/6 inhibitors in HR+/HER2− early breast cancer, in Indian Journal of Cancer!
• 75 patients
• 12-month iDFS: 90.6%
• Dose modifications: ribociclib 14.2%, abemaciclib 18.1%
#BreastCancer @Mehtaaanuradha

[Debdeep Samaddar @DebdeepSamaddar]

Honoured to present our AL amyloidosis research at IMS 2026, Glasgow. My heartfelt thanks to Bhausaheb Sir for his mentorship, encouragement and for inspiring my interest in clinical research. Grateful to TMH and our entire team. #IMS2026 #Amyloidosis

[Debdeep Samaddar @DebdeepSamaddar]

IMS 2026 brings together the people shaping the future of myeloma research and care.

The program features the latest science, abstracts, expert discussions, debates, and more!

I will be there, and you should be too.

Join me:
https://t.co/5pQWNtVkCY
#IMS26

[Gaurav Narula MD @DrGauravNarula]

Prof James Allison @NobelPrize laureate @MDAndersonNews delivering the 6th #IOSICON Immuno-Oncology Society of India Oration at Bhubaneswar- history unfolding of the path from bench to bedside of the greatest discovery in cancer in the last few decades 👏🏻👏🏻👏🏻#IndoUSCancerMoonshot

[Debdeep Samaddar @DebdeepSamaddar]

Happy to present our research work on redefining the role of tumor markers in detecting relapse in Testicular Seminoma from one of the largest datasets under the guidence of Amit Joshi sir in ESMO ASIA 2024.

Always blessed to be a part of TMH.

@adidhanawat

[Aditya Dhanawat @adidhanawat]

We, the doctors and staff of Tata Memorial Hospital, Mumbai stand in solidarity with the recent events that have shaken and angered all of us across the country and beyond. We held a silent protest today and demand justice to be served at the earliest. @TataMemorial @RadOncTMC

[Anant Ramaswamy @AnantRamaswamy]

Does adding Docetaxel in advanced gastric cancers help? https://t.co/jAVZFpusOL important question in the management of gastric cancers answered in our scenario + genomic data @SirohiBhawna @DrVijayPatil11 @SuyogCancer @sajconline @ISMPOofficial @Shrikhande_SV @VanitaNoronha

[Dr Akhil Kapoor @drakhilkapoor1]

Our Multicenter study led by @VikasO and @AnantRamaswamy published in @JNCI_Now
🏥 Intensifying Chemo in advanced Gastric Ca doesn't improve survivals
🏜 Increases toxicities
🏗 More is NOT always better
@dranuj16 @Bipinesh @TMC_Varanasi @oncodaily @ASCO
https://t.co/J8HG6DB2AV

[Anant Ramaswamy @AnantRamaswamy]

Adjuvant Chemotherapy and Chemoradiation in Gallbladder Cancer https://t.co/rWboSKkMg5
@Amolpatel_dr @DrVijayPatil11 @VanitaNoronha @Shrikhande_SV @IJMPOofficial @sajconline @VirajLavingia @sirohi

[Dr (Prof). Vijay Patil @DrVijayPatil11]

10 year results of addition of Nimotuzumab to Cisplatin and RT. Addition of Nimotuzumab lead to an 10 % increase in 10year OS. ⁦@VanitaNoronha⁩ ⁦@Nandinimenon18⁩ ⁦@ASCO⁩ ⁦@SewantiLimaye⁩ ⁦@ashayoncology⁩ ⁦@SuyogCancer⁩ ⁦@Bhosale26Bharat⁩

[Dr (Prof). Vijay Patil @DrVijayPatil11]

Long term results of Low dose Nivolumab study ⁦@VanitaNoronha⁩ ⁦@Nandinimenon18⁩ ⁦@SuyogCancer⁩ ⁦@Amolpatel_dr⁩ ⁦@SewantiLimaye⁩ ⁦@ASCO⁩. Tripling of survival at 2.5 years.

[Dr (Prof). Vijay Patil @DrVijayPatil11]

Congratulations ⁦@Nandinimenon18⁩. Results in of low dose Bev with CCNU in GBM ⁦@ASCO⁩ ⁦@SuyogCancer⁩ ⁦@Amolpatel_dr⁩ ⁦@docameya⁩

[Prabhat Bhargava, DM (Medical Oncology) @bhargava611]

Happy to present our research @TataMemorial in Operated Gallbladder cancer (India centric cancer) patients at #ASCO24

[Dr Akhil Kapoor @drakhilkapoor1]

Mechanism of resistance to ADCs. Next decade is likely to be ADC dominated. Understanding mechanisms and circumventing resistance is the key to success.

Another point to know: <1% ADC can actually get concentrated in tumors. @GlobOncX @dramitpmc @KNJobanputra @ASCOPost

[Dr (Prof). Vijay Patil @DrVijayPatil11]

https://t.co/6e7kTDRzch
Great achievement @Ravijharkhandi @LungConnectIN @VanitaNoronha

[Dr (Prof). Vijay Patil @DrVijayPatil11]

Long term results of our regimen in EGFR mutation positive NSCLC. The combination is active ⁦@VanitaNoronha⁩ ⁦@Nandinimenon18⁩ ⁦@SuyogCancer⁩ ⁦@LungConnectIN⁩ ⁦@SewantiLimaye⁩ ⁦@ns_chd⁩ ⁦@Prabhatmalikmd⁩ https://t.co/jRohwHX6wZ

[Lingaraj Nayak @lingarajnayak]

Real world outcome of AYA lymphoma (677 patients) from eight centres across India.

⁦@MirghSumeet⁩ ⁦@hkJain_kmc⁩ ⁦@DrNikitaMehra⁩ ⁦@Prasshmehta⁩ ⁦@faheema_hasan⁩ ⁦@nihardesai7⁩ ⁦⁦@HCC_HemeCancer⁩ #ASH2023

[Amandeep Arora @dramandeeparora]

Oncosurg 2023

19th annual live surgical fest @TataMemorial

@drgaganprakash did a stellar job with a 3 cm 'stuck' mass for a post chemo RPLND for a testicular NSGCT. Great fun to assist him !!

[Dr (Prof). Vijay Patil @DrVijayPatil11]

Long-term outcomes of neo-adjuvant chemotherapy on borderline resectab... https://t.co/anjvGkVZ0G. 10 year results with Bordeline oral cavity cancer @DrEzraCohen @VanitaNoronha @Nandinimenon18

[Prof Vikas Ostwal @VikasO]

https://t.co/VOwuVoYP1F

Breaking the difficult disease with the help of precision oncology and personalised treatment! @TMCcelebrates75 @MedscapeOnc ogy